Daewoong Pharmaceutical Signs Supply Agreement With Korea Healthcare Association for Wearable ECG Patch 'Mobicare'
Jul 19, 2024
|
Daewoong Pharmaceutical and Health Cooperative plan to use MobiCare to diagnose related diseases such as arrhythmia early and increase treatment efficiency. Daewoong Pharmaceutical supplies MobiCare to 17 health examination centers (MEDICHECK) nationwide, and provides AI reading and expert analysis results for ECG test items, interpretation and consultation explanation materials, and usage education. The Korea Health Association plans to expand the use of AI electrocardiogram tests, which are newly started, by promoting them to health examiners.
Prior to the full-scale introduction, Daewoong Pharmaceutical and Konhyup confirmed the effectiveness of AI electrocardiogram tests using MobiCare. A total of 71 subjects were pre-tested and arrhythmia was detected in about 15% of examinees to prove the effectiveness of early diagnosis of heart disease.
The AI electrocardiogram test conducted in the health cooperative is conducted in two types: 'day' and '1 day (24 hours)' depending on the examinee's choice. In particular, the daily inspection will provide a home collection service. This is to minimize the inconvenience that occurs in the process of returning MobiCare after returning home with a medical examination attached to the chest.
MobiCare is light enough to weigh only 19 grams, is easy to attach and detach, and it does not interfere with daily life such as taking a shower or exercising, so the convenience of the examinee is very high. In addition, it is possible to measure ECG for up to 9 days compared to conventional ECG tests that measure ECG for about 10 seconds during a medical examination, helping to find hidden heart diseases of the examinee. The developer is a digital healthcare company 'Sears Technology'.
Kim In-won, chairman of the Korea Health Association, said "As the elderly population increases and dietary habits become westernized, the number of patients with arrhythmia is also increasing. We expect the efficiency of treatment by increasing the detection rate of arrhythmia disease as well as heart disease by combining 12-induced and continuous electrocardiography together."
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said "Mobicare is attracting attention as a next-generation electrocardiogram solution that improves accuracy, convenience, and economy by supplementing the shortcomings of existing inspection devices such as halters."This MobiCare supply contract will contribute to the promotion of public health by popularizing AI electrocardiogram solutions and increasing the efficiency of early diagnosis and treatment of related diseases."
compact@sportschosun.com
